Salem Investment Counselors’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $775 | Hold |
167
| – | – | ﹤0.01% | 1164 |
|
|
2026
Q1 | $466 | Buy |
+167
| New | +$508 | ﹤0.01% | 1170 |
|
|
2025
Q4 | – | Sell |
-167
| Closed | -$708 | – | 677 |
|
|
2025
Q3 | $708 | Hold |
167
| – | – | ﹤0.01% | 1145 |
|
|
2025
Q2 | $353 | Hold |
167
| – | – | ﹤0.01% | 1129 |
|
|
2025
Q1 | $204 | Hold |
167
| – | – | ﹤0.01% | 1181 |
|
|
2024
Q4 | $216 | Hold |
167
| – | – | ﹤0.01% | 1155 |
|
|
2024
Q3 | $460 | Hold |
167
| – | – | ﹤0.01% | 1135 |
|
|
2024
Q2 | $378 | Hold |
167
| – | – | ﹤0.01% | 1120 |
|
|
2024
Q1 | $400 | Hold |
167
| – | – | ﹤0.01% | 1126 |
|
|
2023
Q4 | $278 | Hold |
167
| – | – | ﹤0.01% | 1075 |
|
|
2023
Q3 | $321 | Hold |
167
| – | – | ﹤0.01% | 1059 |
|
|
2023
Q2 | $241 | Hold |
167
| – | – | ﹤0.01% | 1109 |
|
|
2023
Q1 | $351 | Hold |
167
| – | – | ﹤0.01% | 1066 |
|
|
2022
Q4 | $189 | Hold |
167
| – | – | ﹤0.01% | 1051 |
|
|
2022
Q3 | $0 | Hold |
167
| – | – | ﹤0.01% | 1061 |
|
|
2022
Q2 | $0 | Hold |
167
| – | – | ﹤0.01% | 1086 |
|
|
2022
Q1 | $0 | Hold |
167
| – | – | ﹤0.01% | 1034 |
|
|
2021
Q4 | $0 | Hold |
167
| – | – | ﹤0.01% | 1080 |
|
|
2021
Q3 | $1K | Hold |
167
| – | – | ﹤0.01% | 937 |
|
|
2021
Q2 | $1K | Hold |
167
| – | – | ﹤0.01% | 864 |
|
|
2021
Q1 | $0 | Hold |
167
| – | – | ﹤0.01% | 878 |
|
|
2020
Q4 | $0 | Hold |
167
| – | – | ﹤0.01% | 809 |
|
|
2020
Q3 | $0 | Hold |
167
| – | – | ﹤0.01% | 707 |
|
|
2020
Q2 | $1K | Hold |
167
| – | – | ﹤0.01% | 670 |
|
|
2020
Q1 | $0 | Hold |
167
| – | – | ﹤0.01% | 683 |
|
|
2019
Q4 | $0 | Hold |
167
| – | – | ﹤0.01% | 694 |
|
|
2019
Q3 | $1K | Hold |
167
| – | – | ﹤0.01% | 626 |
|
|
2019
Q2 | $1K | Buy |
+167
| New | +$723 | ﹤0.01% | 649 |
|
|
2018
Q3 | – | Sell |
-167
| Closed | -$1K | – | 472 |
|
|
2018
Q2 | $1K | Buy |
+167
| New | +$813 | ﹤0.01% | 517 |
|
|
2018
Q1 | – | Sell |
-167
| Closed | -$1K | – | 533 |
|
|
2017
Q4 | $1K | Buy |
+167
| New | +$422 | ﹤0.01% | 540 |
|
|
2017
Q3 | – | Sell |
-167
| Closed | – | – | 608 |
|
|
2017
Q2 | $0 | Buy |
+167
| New | +$445 | ﹤0.01% | 682 |
|
Other funds holding GALT
WANY
Salem Investment Counselors's GALT Position: Q2 2026 in Review
Salem Investment Counselors held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 167 shares worth $775. The position accounts for ﹤0.01% of the portfolio, ranked #1164.
Salem Investment Counselors first reported a position in GALT in Q2 2017 and has held it in 31 quarters since. The position peaked at $1K in Q3 2021. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.
- Salem Investment Counselors held 167 shares of Galectin Therapeutics worth $775 as of Q2 2026.
- Salem Investment Counselors left its Galectin Therapeutics share count unchanged in Q2 2026.
- Galectin Therapeutics made up ﹤0.01% of Salem Investment Counselors's portfolio in Q2 2026, its #1164 holding.
- Salem Investment Counselors first reported a position in Galectin Therapeutics in Q2 2017 and has held it in 31 quarters since.
- Salem Investment Counselors's Galectin Therapeutics position peaked at $1K in Q3 2021.
- 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.
Based on Salem Investment Counselors's 13F filing for Q2 2026, filed 14 Jul 2026.